Serum inhibin during lactation: relation to the gonadotrophins and gonadal steroids

Burger, Henry; Hee, Jennifer; Mamers, Pam; Bangah, Mohan; Zissimos, M; McCloud, Philip

doi:10.1111/j.1365-2265.1994.tb02792.x

Cited by 19 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to the potential advantage of interpreting AMH and inhibin B over FSH in the setting of tamoxifen use, all three of these biomarkers have been useful in delineating specific stages in the natural transition to menopause 16, 25–29. Changes in AMH and inhibin B appear to occur earlier than FSH in the natural menopausal transition, seem to reflect subtle changes in ovarian reserve compared to FSH, and may predict time to final menstrual period better than FSH 28, 30–33. They may play a similar role in the transition to menopause for breast cancer patients, a hypothesis that warrants future investigation.…”

Section: Discussionmentioning

confidence: 99%

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors

Sammel

Green

et al. 2009

Cancer

107

View full text Add to dashboard Cite

BACKGROUND:In late reproductive-aged breast cancer survivors, there is a need for real-time biomarkers of postchemotherapy ovarian function. The objective was to determine whether antimullerian hormone (AMH) and inhibin B are such biomarkers. The authors tested whether AMH and inhibin B were impacted by breast cancer treatment by comparing cancer survivors to age-matched control women and determined the association between these hormones and postchemotherapy menstrual pattern. METHODS: Breast cancer patients (n ¼ 127) with American Joint Committee on Cancer stage I to III disease who were premenopausal at diagnosis were enrolled postchemotherapy and observed. The primary endpoint was chemotherapy-related amenorrhea (CRA) (!12 months of amenorrhea after chemotherapy). Matched pair analyses compared AMH, inhibin B, and follicle-stimulating hormone (FSH) levels between cancer and age-matched control subjects. Associations between hormones, CRA status, and change in CRA status over time were assessed. RESULTS: The median age of the patients at chemotherapy was 43.2 years (range, 26.7-57.8 years). At enrollment, median follow-up since chemotherapy was 2.1 years, and 55% of subjects had CRA. Compared with age-matched controls, cancer subjects had significantly lower AMH (P ¼ .004) and inhibin B (P < .001) and higher FSH (P < .001). AMH (P ¼ .002) and inhibin B (P ¼ .001) were found to be significantly associated with risk of CRA, even after controlling for FSH. AMH was significantly lower (P ¼ .03) and FSH was significantly higher (P ¼ .04) in menstruating subjects who developed subsequent CRA. CONCLUSIONS: AMH and inhibin B are 2 additional measures of postchemotherapy ovarian function in late reproductive-aged breast cancer survivors. With further research and validation, these hormones may supplement limited current tools for assessing and predicting postchemotherapy ovarian function. Cancer 2010;116:592-9.

show abstract

Section: Discussionmentioning

confidence: 99%

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors

Sammel

Green

et al. 2009

Cancer

107

View full text Add to dashboard Cite

show abstract

“…But this particular response to ovarian failure is probably protected evolutionarily because it is physiologically important and logical in another circumstance. Specifically, FSH rises to a fairly high plateau, typically over 10 mIU/mL and sometimes exceeding 20 mIU/mL, for prolonged periods during lactation, 30 when estrogen is also low. Often below normal levels for cycling women, but usually not as low as in the menopause.…”

Section: Fsh Drives Bone Resorptionmentioning

confidence: 99%

Skeletal receptors for steroid‐family regulating glycoprotein hormones

Blair

Robinson

Sun

et al. 2011

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Pituitary glycoprotein hormone receptors, including ACTH-R, TSH-R, and FSH-R, occur in bone. Their skeletal expression reflects that central endocrine control is evolutionarily recent. ACTH receptors, in osteoblasts or the adrenal cortex, drive VEGF synthesis. VEGF is essential to maintain vasculature. In bone, ACTH suppression by glucocorticoids can cause osteonecrosis. TSH receptors occur on osteoblasts and osteoclasts, in both cases reducing activity. Thus, TSH directly reduces skeletal turnover, consistent with evolutionary adaptation to stress. FSH receptors accelerate bone resorption, whereas estrogen promotes bone formation, the forces usually balancing. With ovarian failure, low estrogen with high FSH causes rapid bone loss. The skeletal FSH effect in the menopause seems paradoxical, but it is a logical adaptation in lactation, where prolonged FSH elevation also occurs. In addition to receptors, there is some synthesis of pituitary glycoproteins at distributed sites; this is not well studied, but it may further modify the paradigm of central endocrine regulation.

show abstract

“…The study of hormone levels during lactation has been described in detail previously. (Burger et al, 1994) In that study a total of 29 women were recruited in the third trimester, prior to delivery. Eighteen of these provided data for the prior study.…”

Section: Methodsmentioning

confidence: 99%

“…A previous study from this laboratory (Burger et al, 1994) examined the physiology of serum immunoreactive inhibin (a term used for a-subunit inhibin containing peptides) during lactation. In this study inhibin levels were shown to fall rapidly postpartum and to remain low until close to the time of resumption of follicular activity and menses.…”

mentioning

confidence: 99%

“…Previous reports had indicated that immunoreactive inhibin measurements generally re¯ected the behaviour of inhibin A, but not of inhibin B (Groome et al, 1996) and it was therefore of interest to determine whether there may be a pattern of differential secretion of the two inhibins at a time when no dominant follicle would be present in the ovary. The present study measured inhibins A and B in samples available from the previous investigation (Burger et al, 1994).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Inhibins A and B are regulated differentially in the early post‐partum period

Burger¹,

Mamers

Groome

2000

Clinical Endocrinology

View full text Add to dashboard Cite

The secretion of inhibin A and B is regulated differentially during the early stages of lactational amenorrhoea, just as it is in the late luteal phase of the normal menstrual cycle. Whilst inhibin A falls postpartum, reflecting cessation of placental function, and remains low until ovulatory cycles are resumed, FSH and inhibin B rise after a delay of two weeks or more. It is postulated that the rise of inhibin B is the result of secretion from a cohort of small follicles stimulated by rising FSH levels.

show abstract

Serum inhibin during lactation: relation to the gonadotrophins and gonadal steroids

Cited by 19 publications

References 24 publications

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors

Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive‐aged breast cancer survivors

Skeletal receptors for steroid‐family regulating glycoprotein hormones

Inhibins A and B are regulated differentially in the early post‐partum period

Contact Info

Product

Resources

About